Patents Examined by George W Kosturko
  • Patent number: 11911356
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for the treatment of cancer characterized by TERT and BRAF mutations. In a specific embodiment, a method for treating a mutant telomerase reverse trancriptase (TERT) enzyme-associated cancer in a subject comprises the step of administering to the subject an anti-cancer agent that inhibits one or more of FOS, GABPB, the formation of the GABPA-GABPB complex or the binding of the GABPA-GABPB complex to a mutant TERT promoter.
    Type: Grant
    Filed: December 22, 2018
    Date of Patent: February 27, 2024
    Assignee: The Johns Hopkins University
    Inventors: Michael Mingzhao Xing, Rengyun Liu
  • Patent number: 11911381
    Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: February 27, 2024
    Assignee: Sumitomo Pharma Co., Ltd.
    Inventors: Seiji Kamioka, Hitoshi Ban, Naoaki Shimada, Wataru Hirose, Akihiko Arakawa, Kazuto Yamazaki, Kenjiro Hira
  • Patent number: 11912708
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Grant
    Filed: June 2, 2023
    Date of Patent: February 27, 2024
    Inventors: Baogen Wu, Pingda Ren, Zhiyong Chen, Yi Liu
  • Patent number: 11913077
    Abstract: A method of treating a cancer in a patient includes obtaining a sample from the patient, using a C-circle assay to detect a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, and administering an effect amount of at least one of PRIMA-1 or APR-246 to the patient.
    Type: Grant
    Filed: March 9, 2019
    Date of Patent: February 27, 2024
    Assignee: Texas Tech University System
    Inventors: Charles Patrick Reynolds, Balakrishna Koneru, Shawn Macha
  • Patent number: 11903914
    Abstract: This invention discloses uses for sulindac in preparing anti-lung cancer products. This invention provides uses for sulindac in the preparation of products to treat lung cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug sulindac, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that sulindac has a new use as an anti-lung cancer medication, thus achieving a new purpose for an old drug.
    Type: Grant
    Filed: May 26, 2021
    Date of Patent: February 20, 2024
    Inventors: Yongyong Shi, Zhijian Song
  • Patent number: 11896579
    Abstract: The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an ALK inhibitor and a VEGF inhibitor. The present invention also relates to a method for treating or preventing cancer and a method for inhibiting tumor growth.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: February 13, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroshi Sakamoto, Toshiyuki Tsukaguchi
  • Patent number: 11890286
    Abstract: Methods and compositions for treating cancer are disclosed.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: February 6, 2024
    Assignee: The University of Chicago
    Inventors: Ali Ekram Yesilkanal, Marsha Rosner
  • Patent number: 11878049
    Abstract: Described herein are methods of treating pyruvate kinase deficiency (PKD), sickle cell disease or thalassemia with mitapivat or a pharmaceutically acceptable salt thereof, or use of the drug for the treatment of these conditions, in combination with or in the absence of with a secondary drug, such as an inducer or an inhibitor of cytochrome P450. Various doses and dosing regimens of mitapivat in monotherapy and in concomitant medications are described.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: January 23, 2024
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Varsha Venkatachalam Iyer, Chandra Agarwal Prakash, Hua Yang
  • Patent number: 11857630
    Abstract: This disclosure relates to the field of formulations of SN-38 with a poly(amino acid) copolymer and methods of making and using thereof. Compositions herein are drug products suitable for the treatment of cancer.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: January 2, 2024
    Inventors: Kevin N. Sill, Bradford T. Sullivan
  • Patent number: 11858940
    Abstract: Bifunctional compounds, which find utility as modulators of non-receptor Leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: January 2, 2024
    Assignee: Arvinas Operations, Inc.
    Inventors: Erika Araujo, Michael Berlin, Steven M. Sparks, Jing Wang, Wei Zhang
  • Patent number: 11834553
    Abstract: Among other aspects, provided herein is a mixed-acid salt of a water-soluble polymer-drug conjugate, along with related methods of making and using the same. The mixed-salt acid salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding predominantly pure acid salt or free base forms of the polymer-drug conjugate. The mixed acid salt is reproducibly prepared and recovered, and provides surprising advantages over non-mixed acid salt forms of the water-soluble polymer drug conjugate.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: December 5, 2023
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, Samuel P. McManus, Sachin Tipnis, Greg Lavaty, David Swallow, John R. Handley, Anthony G. Schaefer
  • Patent number: 11826365
    Abstract: The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 28, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Hwan Geun Choi, Xianming Deng, Jianming Zhang
  • Patent number: 11801232
    Abstract: This application relates to methods and kits for treating ARID1A-mutant tumors, cancers, or aberrantly proliferating cells and subjects harboring the tumors, cancers, or aberrantly proliferating cells. In particular, the methods provided include administering to the subject or cell an effective amount of a pyrimidine synthesis inhibitor and administering to the subject or cell an effective amount of a DNA repair inhibitor. The kits include a) a composition comprising a pyrimidine synthesis inhibitor and b) a composition comprising a DNA repair inhibitor.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: October 31, 2023
    Inventor: Gloria Huang
  • Patent number: 11793816
    Abstract: Disclosed are methods and compositions for treating cell proliferative diseases and disorders such as cancers. Particularly disclosed are methods and composition for treating cancers such as glioblastoma by administering a therapeutic agent that inhibits the biological activity of the autophagy related 4B cysteine peptidase (ATG4B) protein in conjunction with additional therapeutic agents or treatments.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: October 24, 2023
    Assignee: Northwestern University
    Inventors: Shi-Yuan Cheng, Bo Hu, Tianzhi Huang
  • Patent number: 11786529
    Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-actyloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody. The potent and selective BTK inhibitor in combination with the anti-PD-1 antibody have a manageable toxicity profile in patients with indolent and aggressive lymphomas.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: October 17, 2023
    Inventors: James Hilger, Xiaoping Zhang, Shibao Feng, Sunhee Ro, Jane Huang
  • Patent number: 11780963
    Abstract: The disclosure provides a multi-arm multi-claw polyethylene glycol derivative suitable for click chemistry reactions of general formula I, wherein R is a polyethylene glycol residue having a linear-chain structure, a Y-type structure or a multi-branched structure, R1, R2 and R3 are linking groups, P is an terminal group of non-azido non-alkynyl group, D is —N3 or —C?CH, l is selected from an integer of 1 to 20, and m is selected from an integer of 0 to 19.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: October 10, 2023
    Inventors: Yanli Xiong, Jinliang Wang, Zewang Feng, Lihui Zheng, Xuan Zhao
  • Patent number: 11771709
    Abstract: A compound of formula (I) and its antitumor application are disclosed. The compounds of formula (I) have degradation and inhibitory effects on ALK target proteins. They are mainly composed of four parts: the first part, ALK-TKI, being compounds with ALK tyrosine kinase inhibitory activity; the second part, LIN, being different kinds of linker (Linker); the third part, the ULM, being a small molecule ligand (ULM, ubiquitin ligase binding moiety) with ubiquitination of VHL, CRBN or other proteases; and the fourth part, the group A, being a carbonyl group or absent, which covalently bond ALK-TKI to LIN, wherein LIN and ULM are covalently bonded. A series of compounds designed and synthesized by the present disclosure have wide pharmacological activities, have functions of degrading ALK protein and inhibiting ALK activity, and can be used for related tumor treatment.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: October 3, 2023
    Assignee: ShanghaiTech University
    Inventors: Xiaobao Yang, Biao Jiang, Xiaoling Song, Haifan Lin, Ning Sun, Jinju Chen, Xing Qiu, Chaowei Ren, Ying Kong
  • Patent number: 11766436
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: September 26, 2023
    Assignee: Amgen Inc.
    Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
  • Patent number: 11758929
    Abstract: A powdered pre-operative beverage composition has one or more carbohydrates and L-citrulline. The composition can further have a CNS stimulant, a sweetener, citric acid, L-theanine, zinc sulfate, sodium selenite, Vitamin A, and at least one flavor enhancing agent. The composition remains clear when mixed with water. The composition, when mixed with water has an osmolarity of about 265 milliosmole to about 300 milliosmole and a pH about 3.7 to about 4.5. A total energy available from the one or more carbohydrates in one serving of the composition is at least about 200 calories.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: September 19, 2023
    Assignee: ClearFast Inc.
    Inventor: M. Lou Marsh
  • Patent number: 11737993
    Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: August 29, 2023
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan